Originally aired: US (ET): Thursday, November 6, 11:00am – 11:30am

Access this webinar to learn how Model-Informed Drug Development (MIDD) provides a de-risked, evidence-based approach to attract funding, build investor confidence, and strengthen due diligence in today’s challenging market—where extended development timelines and cautious investors make fundraising and partnerships more complex.

Far beyond its regulatory applications, MIDD enables companies to assess market potential, evaluate competitive positioning, and make data-driven investment decisions. In this on-demand session, Certara’s experts share how MIDD and Modeling & Simulation (M&S) play pivotal roles in asset valuation, dose justification, and target population selection—ultimately driving greater success in drug development and licensing.

You’ll Learn How To:

Use MIDD approaches to support buyer assessment
Apply MIDD as a tool to enhance asset value from the seller’s perspective
Leverage MIDD as a digital twin for virtual evaluation
See how the approach helps both small and large companies

Intended Audience

Buyers: Venture capital and large pharma exploring in-licensing, partnerships, or acquisitions
Sellers: Bioventures and small-to-mid-size pharma pursuing out-licensing, partnerships, or acquisitions

Featuring:

Fran Brown, PhD, Senior Vice President, Certara Drug Development Solutions
Amy Cheung, PhD, Vice President, Certara Drug Development Solutions

View the On-Demand Recording